FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to the field of immunology. Disclosed is a method of treating rheumatoid arthritis, chronic arthritis in children or Castelman's disease, application of an antibody in the said method, as well as application of an antibody in production of a medication for treatment of rheumatoid arthritis, chronic arthritis in children or Castelman's disease. The antibody by the claimed invention possesses an improved antigen-neutralising ability, pharmacokinetics, immunogenicity, safety and physicochemical properties and can be further applied in therapy of diseases, associated with the activation of the receptor IL-6.
EFFECT: claimed is the medication for treatment of rheumatoid arthritis, chronic arthritis in children or Castelman's disease, representing the antibody against the receptor IL-6, obtained on the basis of the antibody TOCILIZUMAB.
12 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADVANCED ANTIBODY MOLECULES | 2009 |
|
RU2430111C1 |
| PHARMACEUTICAL FORMULATION CONTAINING ADVANCED ANTIBODY MOLECULES | 2010 |
|
RU2565809C2 |
| METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2012 |
|
RU2670743C9 |
| ANTIGEN-BINDING MOLECULE CAPABLE OF REPEATEDLY BINDING TWO OR MORE ANTIGEN MOLECULES | 2009 |
|
RU2571225C2 |
| NR10 ANTIBODY AND USING IT | 2008 |
|
RU2531521C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| ANTIBODY AGAINST NR10 AND ITS APPLICATION | 2009 |
|
RU2487136C2 |
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| PAIN TREATMENT | 2009 |
|
RU2712166C2 |
